Pelthos Therapeutics Acquires Xepi, Expands Dermatology Portfolio

Pelthos Therapeutics has acquired the US commercialization rights to Xepi, a topical treatment for impetigo, from Biofrontera. Xepi is a novel FDA-approved treatment for antibiotic-resistant skin infections caused by staph and strep infections, affecting approximately 3 million people in the US annually. The acquisition will be financed through private convertible notes, supporting the re-launch of Xepi, accelerating the commercialization of ZELSUVMI for molluscum contagiosum, and for general working capital purposes.